SIRT1 and myelodysplastic syndrome: The SIRT1 activator SRT1720 and the SIRT1 agonist SRT2104 were able to inhibit HSPCS MDS colony formation in murine models by SIRT1-induced TET2 acetylation reversing the dysplastic phenotype, moreover, the expression of SIRT1 and TET2 target genes was also positively regulated in MDS CD34+ cells after SRT1720 treatment [56].